CaMMouflage
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 50 patients (estimated)
- Sponsors
- Caribou Biosciences, Inc.
- Tags
- CAR T Cell (Allogeneic), B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1351
- NCT Identifier
- NCT05722418
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.